Equifax Price Target Trimmed as Stock Multiple Adjusted to Downside

Barclays analysts recently made a notable change in their outlook for Equifax (NYSE: EFX), downgrading the stock from Overweight to Equal Weight. Equifax’s stock price shed 9.37% on Friday, as markets were gripped by tariff talks,.

The price target has been significantly reduced from $325 to $260. This adjustment underscores Barclays’ concerns about various market risks affecting Equifax, and coming on broader market declines only serve to accentuate the sentiment.

Equifax, which is currently trading at a high valuation level with a Price-to-Earnings (P/E) ratio of 43x, has experienced an 16.3% decline in its stock value year-to-date. The company’s beta of 1.65 indicates it is subject to higher volatility compared to the overall market.

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

Despite this, Equifax’s recent performance shows some positive aspects. The firm’s estimated first-quarter 2025 revenue, adjusted EBITDA, and adjusted EPS are slightly above the initial guidance, with increases of $27 million, $10 million, and $0.05 respectively. However, for the full year 2025, estimates for revenue, adjusted EBITDA, and adjusted EPS have been slightly revised downwards by $14 million, $11 million, and $0.06 respectively from previous estimates.

Further weighing on the stock’s outlook, Barclays applied approximately 22 times the forecasted adjusted EPS for fiscal year 2027, discounted by 10%, while previously it was based on a multiple of 27 times. This change reflects the bank’s updated valuation assessment of Equifax’s future earnings potential.

On a different note, other analysts have contrasting views. RBC Capital Markets upgraded Equifax’s stock to Outperform, setting a target price of $300, citing the anticipated recovery in the mortgage market and FICO price increases as positive factors.